Brian W. Slafer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Brian W. Slafer has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Alexander Bondke
8 shared publications- Alison Harrod
Division of Cell and Molecular Biology, The Institute of Cancer Research; London, UK
8 shared publications - Anthony G. M. Barrett
Department of Chemistry Imperial College London Molecular Sciences Research Hub White City Campus, 82 Wood Lane London W12 0BZ UK
8 shared publications - Eric Ofori Aboagye
Department of Surgery and Cancer, Imperial College London, London, UK
8 shared publications - Georgina P. Sava
Division of Cancer, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK
8 shared publications Laki Buluwela
8 shared publications
Latest Publications
- Open Access
- 13 May 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 9 (20) , 22360-22370
Synthesis and Anti-Trypanosoma cruzi Activity of 3-Cyanopyridine Derivatives
Chagas disease (CD) is a parasitic neglected tropical disease (NTD) caused by the protozoan Trypanosoma cruzi that affects 6 million people worldwide, often resulting in financial burden, morbidity, and mortality in endemic regions. Given a lack of highly efficient and safe treatments, new, affordable, and fit-for-purpose drugs for CD are urgently needed. In this work, we present a hit-to-lead campaign for novel cyanopyridine analogues as antichagasic agents. In a phenotypic screening against intracellular T. cruzi, hits 1 and 2 were identified and displayed promising potency combined with balanced physicochemical properties. As part of the Lead Optimization Latin America consortium, a set of 40 compounds was designed, synthesized, and tested against T. cruzi intracellular amastigotes and relevant human cell lines. The structural modifications were focused on three positions: cyanopyridine core, linker, and right-hand side. The ADME properties of selected compounds, lipophilicity, kinetic solubility, permeability, and liver microsomal stability, were evaluated. Compounds 1-9 displayed good potency (EC50T. cruzi amastigote 50 MRC-5 = 32-64 μM). Despite the good balance between potency and selectivity, the antiparasitic activity of the series appeared to be driven by lipophilicity, making the progression of the series unfeasible due to poor ADME properties and potential promiscuity issues.
- 13 May 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 9 (20) , 22360-22370
Open AccessSynthesis and Anti-Trypanosoma cruzi Activity of 3-Cyanopyridine Derivatives
Chagas disease (CD) is a parasitic neglected tropical disease (NTD) caused by the protozoan Trypanosoma cruzi that affects 6 million people worldwide, often resulting in financial burden, morbidity, and mortality in endemic regions. Given a lack of highly efficient and safe treatments, new, affordable, and fit-for-purpose drugs for CD are urgently needed. In this work, we present a hit-to-lead campaign for novel cyanopyridine analogues as antichagasic agents. In a phenotypic screening against intracellular T. cruzi, hits 1 and 2 were identified and displayed promising potency combined with balanced physicochemical properties. As part of the Lead Optimization Latin America consortium, a set of 40 compounds was designed, synthesized, and tested against T. cruzi intracellular amastigotes and relevant human cell lines. The structural modifications were focused on three positions: cyanopyridine core, linker, and right-hand side. The ADME properties of selected compounds, lipophilicity, kinetic solubility, permeability, and liver microsomal stability, were evaluated. Compounds 1-9 displayed good potency (EC50T. cruzi amastigote 50 MRC-5 = 32-64 μM). Despite the good balance between potency and selectivity, the antiparasitic activity of the series appeared to be driven by lipophilicity, making the progression of the series unfeasible due to poor ADME properties and potential promiscuity issues.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4. from ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
ADME analysis, oral bioavailability and distribution of ICEC0942.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4. from ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
ADME analysis, oral bioavailability and distribution of ICEC0942.